Drug
VX 522 Mrna Therapy
VX 522 Mrna Therapy: highest development phase Phase 1/2, developed by Vertex Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Vertex Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| VX-522 mRNA therapy NCT05668741 | Phase 1/2 | Cystic Fibrosis |
Latest
No recent events.
Follow VX 522 Mrna Therapy on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.